Free Trial

Nyxoah Q2 2024 Earnings Report

Nyxoah logo
$6.08 -0.91 (-13.02%)
As of 04:00 PM Eastern

Nyxoah EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.45
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
$0.83 million
Expected Revenue
$1.93 million
Beat/Miss
Missed by -$1.10 million
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Nyxoah Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Kepler Capital Remains a Buy on Nyxoah (NYXH)
HC Wainwright Has Positive Outlook for Nyxoah Q1 Earnings
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

View Nyxoah Profile

More Earnings Resources from MarketBeat